Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 314

  • The following term was ignored: -
  • See the search details.
1.

[Is the PAP smear era coming to an end?].

Nowak-Markwitz E, Spaczyński M.

Ginekol Pol. 2015 Dec;86(12):947-50. Review. Polish.

PMID:
26995946
2.

Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening.

Wang SM, Hu SY, Chen W, Chen F, Zhao FH, He W, Ma XM, Zhang YQ, Wang J, Sivasubramaniam P, Qiao YL.

BMC Cancer. 2015 Nov 4;15:848. doi: 10.1186/s12885-015-1882-9.

3.

Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.

Solares C, Velasco J, Álvarez-Ruiz E, González-Fernández L, Encinas AI, Astudillo A, Schneider J.

Anticancer Res. 2015 Nov;35(11):6291-5.

PMID:
26504065
4.

[Prevalence of cytological atypia and high-risk human papillomavirus infection in Panará indigenous women in Central Brazil].

Rodrigues DA, Pereira ÉR, Oliveira LS, Speck NM, Gimeno SG.

Cad Saude Publica. 2014 Dec;30(12):2587-93. doi: 10.1590/0102-31l'1X00152713. Portuguese.

5.

HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status.

Richardson LA, El-Zein M, Ramanakumar AV, Ratnam S, Sangwa-Lugoma G, Longatto-Filho A, Cardoso MA, Coutlée F, Franco EL; PEACHS (Pap Efficacy After Cervical HPV Status) Study Consortium.

Cancer Cytopathol. 2015 Dec;123(12):745-54. doi: 10.1002/cncy.21596. Epub 2015 Jul 31.

PMID:
26230283
6.

A novel highly sensitive and specific flow cytometry system for cervical cancer screening.

Han X, Ping B, Morita M, Ebi R, Inoue J, Tanaka Y, Chen Y, Wan X, Yang W, Chang B, Wu X.

Gynecol Oncol. 2015 Oct;139(1):52-8. doi: 10.1016/j.ygyno.2015.07.102. Epub 2015 Jul 23.

PMID:
26212521
7.

The Korean guideline for cervical cancer screening.

Min KJ, Lee YJ, Suh M, Yoo CW, Lim MC, Choi J, Ki M, Kim YM, Kim JW, Kim JH, Park EW, Lee HY, Lim SC, Cho CH, Hong SR, Dang JY, Kim SY, Kim Y, Lee WC, Lee JK.

J Gynecol Oncol. 2015 Jul;26(3):232-9. doi: 10.3802/jgo.2015.26.3.232.

8.

30 years of preventive studies of uterine cervical cancer 1982-2012.

Garrido JL.

Eur J Gynaecol Oncol. 2015;36(3):252-4.

PMID:
26189248
9.

Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.

Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Elwood Martin R, Franco EL, Ogilvie G.

J Obstet Gynaecol Can. 2015 May;37(5):412-20.

PMID:
26168101
10.

Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.

Fokom-Domgue J, Combescure C, Fokom-Defo V, Tebeu PM, Vassilakos P, Kengne AP, Petignat P.

BMJ. 2015 Jul 3;351:h3084. doi: 10.1136/bmj.h3084. Review.

11.

[Knowledge of human papilloma virus (HPV) and acceptance of vaginal self-sampling among Mexican woman].

Hernández-Márquez CI, Salinas-Urbina AA, Cruz-Valdez A, Hernández-Girón C.

Rev Salud Publica (Bogota). 2014 Sep-Oct;16(5):697-708. Spanish.

12.

Perceived effectiveness of HPV test as a primary screening modality among US providers.

Cooper CP, Saraiya M.

Prev Med. 2015 Sep;78:33-7. doi: 10.1016/j.ypmed.2015.06.007. Epub 2015 Jun 24.

PMID:
26116889
13.

History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.

Tao X, Griffith CC, Zhou X, Wang Z, Yan Y, Li Z, Zhao C.

Cancer Cytopathol. 2015 Jul;123(7):421-7. doi: 10.1002/cncy.21545. Epub 2015 May 8.

PMID:
25955972
14.

Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.

Zheng B, Li Z, Griffith CC, Yan S, Chen C, Ding X, Liang X, Yang H, Zhao C.

Cancer Cytopathol. 2015 Jul;123(7):428-34. doi: 10.1002/cncy.21557. Epub 2015 May 8.

PMID:
25954852
15.

Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.

Miller RA, Mody DR, Tams KC, Thrall MJ.

Arch Pathol Lab Med. 2015 Nov;139(11):1431-6. doi: 10.5858/arpa.2014-0633-OA. Epub 2015 May 7.

PMID:
25951104
16.

Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.

Sawaya GF, Kulasingam S, Denberg TD, Qaseem A; Clinical Guidelines Committee of American College of Physicians.

Ann Intern Med. 2015 Jun 16;162(12):851-9. doi: 10.7326/M14-2426.

PMID:
25928075
17.

Awareness and knowledge regarding of cervical cancer, Pap smear screening and human papillomavirus infection in Gabonese women.

Assoumou SZ, Mabika BM, Mbiguino AN, Mouallif M, Khattabi A, Ennaji MM.

BMC Womens Health. 2015 Apr 19;15:37. doi: 10.1186/s12905-015-0193-2.

19.

[Human papillomavirus testing in cervical cancer screening at a public health service of Santiago, Chile].

Terrazas S, Ibáñez C, Lagos M, Poggi H, Brañes J, Barriga MI, Cartagena J, Núñez F, González F, Cook P, Van De Wyngard V, Ferreccio C.

Rev Med Chil. 2015 Jan;143(1):56-62. doi: 10.4067/S0034-98872015000100007. Spanish. Erratum in: Rev Med Chil. 2015 Mar;143(3):408.

20.

Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.

Ko MJ, Kim J, Kim Y, Lee YJ, Hong SR, Lee JK.

Asian Pac J Cancer Prev. 2015;16(6):2317-22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk